Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib plus bevacizumab maintenance in platinum-sensitive recurrent ovarian cancer after prior PARP inhibitor
KCT0006051Phase 2Recruiting
- Sponsor
- Takeda
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of niraparib and bevacizumab in ovarian cancer, sponsored by Takeda. Started Jul 2021; status: recruiting.
02
Drugs
niraparibbevacizumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on KCT0006051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006051.